1. BioMarker Strategies biotrinity 2016 London April 25-27 Functional Profiling to Guide Cancer Drug Development and Treatment Selection

2. Forward-Looking Statements The information in this presentation includes our projections and other forward-looking statements regarding future events. In some cases, forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “projects,” “estimates,” “predicts,” “potential,” “continue”, etc. These statements are not guarantees of future performance or achievement and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is projected here. 2

3. Dynamic information available only from live cells is required to understand acquired resistance and predict individual response. BioMarker Strategies Founded to Address a Significant Unmet Drug Development and Medical Need Available biomarker tests for solid tumors Primarily rely on dead, fixed tissue samples Provide only indirect information regarding signal transduction pathway response to targeted therapies Useful in identifying mutations, general therapeutic approach Not useful for study of mechanisms of acquired resistance Do not accurately and dependably predict response 3

4. The SnapPath® Cancer Diagnostics System Automated, fluidics-based bench-top instrument  Disposable cartridge holds required consumables and reagents Generates purified populations of live cells  Preserves molecular integrity for ex vivo exposure to targeted therapies on SnapPath® Highly customizable  Compatible with any solid tumor for which fresh, unfixed tissue samples are available  Agnostic as to analytic technique Proof of Concept in advanced melanoma Enables generation of Functional Signaling Profiles SnapPath® patents granted USA, Europe, Australia and Hong Kong 4

5. The SnapPath® Cancer Diagnostics System 5 Functional Profile SnapPath® Automated ProcessingSample

6. Nucleic Acid Sequencing IHC Testing PathMAP® Functional Signaling Profiles A new class of much more predictive biomarker tests Traditional  Direct information about response of signal transduction pathways  Useful for identifying and understanding mechanisms of acquired resistance  Recently awarded P. I/II NCI fast-track grant to develop PathMAP® NSCLC CDx  Ongoing NCI Phase II contract to develop PathMAP® Melanoma CDx  PathMAP® patents granted Australia and Singapore Functional Profiles 6

7. 7 SnapPath®-Assisted Drug Development Companion Diagnostic Target Selection High- throughput Screening Lead Candidate Selection LaunchClinical Trials 123 Identification of bypass mechanisms, feedback loops, alternative targets Lead Candidate Selection Go/No-Go Clinical Trial Patient Stratification Repurposing and New Indications The only diagnostic system that enables automated and standardized ex vivo interrogation of live solid tumor cells.

8. 1.Support business development efforts directed toward entering into funded collaborations with pharma/bio companies. SnapPath® and PathMAP® Functional Signaling Profiles are ideally suited for studies to assess response to investigational targeted therapies:  In model systems such as xenografts and tumorgrafts  In early clinical trials to assess pharmacodynamic changes in solid tumor patients Management expects to enter into the Company’s first preclinical commercial collaboration agreement in second half of 2016. 2.Develop additional proof-of-concept data in multiple solid tumors and targeted therapies. 3.Develop companion diagnostic tests for tumors beyond melanoma with funding from partners, NCI or other nondilutive sources. Raised to date: $9.5 million equity capital + $4.25 million nondilutive Current Funding Objective: $4 Million First $1.5 million raised ($1 million from Novit LP, U.S. investment arm of Poland-based USP Group) 8

9. 5-Year Business Plan (2016-2020) Self-Sustaining Revenues Based on BP assumptions, BioMarker Strategies expects to achieve self- sustaining revenues by YE 2017 – and exit via acquisition within 3-5 years. 9

10. For more information, please contact Jerry Parrott, President and CEO 15601 Crabbs Branch Way, Rockville, MD 20855 mobile 301-938-4043 jparrott@biomarkerstrategies.com jparrott@biomarkerstrategies.com 10